170 related articles for article (PubMed ID: 27434957)
21. Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Guan M; Zhou X; Soulitzis N; Spandidos DA; Popescu NC
Clin Cancer Res; 2006 Mar; 12(5):1412-9. PubMed ID: 16533763
[TBL] [Abstract][Full Text] [Related]
22. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer.
Alberti I; Barboro P; Barbesino M; Sanna P; Pisciotta L; Parodi S; Nicolò G; Boccardo F; Galli S; Patrone E; Balbi C
J Cell Biochem; 2000 Sep; 79(3):471-85. PubMed ID: 10972984
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.
Stephan C; Jung K; Diamandis EP; Rittenhouse HG; Lein M; Loening SA
Urology; 2002 Jan; 59(1):2-8. PubMed ID: 11796270
[No Abstract] [Full Text] [Related]
24. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
[TBL] [Abstract][Full Text] [Related]
25. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
26. [Molecular mechanisms of prostatic oncogenesis].
Zezerov EG; Severin ES
Vestn Ross Akad Med Nauk; 1998; (5):29-35. PubMed ID: 9662994
[TBL] [Abstract][Full Text] [Related]
27. Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.
Reis IM; Ramachandran K; Speer C; Gordian E; Singal R
Br J Cancer; 2015 Jul; 113(3):460-8. PubMed ID: 26171936
[TBL] [Abstract][Full Text] [Related]
28. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
[TBL] [Abstract][Full Text] [Related]
29. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
30. PSCA mRNA expression in preoperatively negative prostate biopsies predicts incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Ma W; Zeng G; Qi D
J Surg Oncol; 2011 Nov; 104(6):672-8. PubMed ID: 21674503
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic value of 10 systematized and ultrasound-guided transrectal prostatic biopsies].
Ravery V; Billebaud T; Toublanc M; Boccon-Gibod L; Hermieu JF; Moulinier F; Blanc E; Delmas V; Boccon-Gibod L
Prog Urol; 1998 Dec; 8(6):1012-7. PubMed ID: 9894260
[TBL] [Abstract][Full Text] [Related]
32. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
33. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
34. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma.
Jerónimo C; Varzim G; Henrique R; Oliveira J; Bento MJ; Silva C; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):445-50. PubMed ID: 12010858
[TBL] [Abstract][Full Text] [Related]
35. Benign mimics of prostatic adenocarcinoma on needle biopsy.
Gaudin PB; Reuter VE
Anat Pathol; 1997; 2():111-34. PubMed ID: 9575372
[TBL] [Abstract][Full Text] [Related]
36. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids.
Goessl C; Krause H; Müller M; Heicappell R; Schrader M; Sachsinger J; Miller K
Cancer Res; 2000 Nov; 60(21):5941-5. PubMed ID: 11085508
[TBL] [Abstract][Full Text] [Related]
37. [New prospective diagnostic serum markers in prostatic cancer].
Mirone V; De Bellis G; Prezioso D; Sanseverino R; Iannucci F; Padulano P
Minerva Med; 1986 Mar; 77(13):503-4. PubMed ID: 2422605
[No Abstract] [Full Text] [Related]
38. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.
Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A
Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626
[TBL] [Abstract][Full Text] [Related]
39. NotI microarrays: novel epigenetic markers for early detection and prognosis of high grade serous ovarian cancer.
Kashuba V; Dmitriev AA; Krasnov GS; Pavlova T; Ignatjev I; Gordiyuk VV; Gerashchenko AV; Braga EA; Yenamandra SP; Lerman M; Senchenko VN; Zabarovsky E
Int J Mol Sci; 2012 Oct; 13(10):13352-77. PubMed ID: 23202957
[TBL] [Abstract][Full Text] [Related]
40. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia.
Singer E; Linehan J; Babilonia G; Imam SA; Smith D; Loera S; Wilson T; Smith S
PLoS One; 2013; 8(6):e60562. PubMed ID: 23762225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
